Literature DB >> 6232890

Effector and regulator functions of splenic and thymic lymphocytes in the clawed toad Xenopus.

E Hsu, M H Julius, L Du Pasquier.   

Abstract

B cells in Xenopus, as characterized by surface immunoglobulin, nylon-wool adherence and ability to produce antibody in vitro, were found in both major lymphoid organs: 10-25% Ig-positive cells for spleen and 0.5-4% for thymus. The splenic and thymic B cells were able to produce specific antibody of both isotypes, IgM and low molecular weight (LMW) Ig (IgG equivalent). While for a T-cell-dependent antigen, DNP-KLH, both required T-cell help, thymic B cells for a specific antigen produced far more LMW Ig than splenic B cells. Thymic T cells had the same ability as splenic T cells to elicit an allogenic GvH, but with much less efficiency, probably as a result of fewer mature cells. In contrast to splenic T cells, thymic T cells provided little or no help for B cells and, in certain instances, demonstrated suppressor activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6232890     DOI: 10.1016/s0769-2625(83)80022-1

Source DB:  PubMed          Journal:  Ann Immunol (Paris)        ISSN: 0300-4910


  4 in total

1.  In vivo studies on allotolerance perimetamorphically induced in control and thymectomized Xenopus.

Authors:  J C Arnall; J D Horton
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

2.  Immunoglobulin Fc receptor molecules on Xenopus laevis splenocytes.

Authors:  V Coosemans; I Hadji-Azimi
Journal:  Immunology       Date:  1988-12       Impact factor: 7.397

3.  Waterborne infectivity of the Ranavirus frog virus 3 in Xenopus laevis.

Authors:  Jacques Robert; Erica George; Francisco De Jesús Andino; Guangchun Chen
Journal:  Virology       Date:  2011-07-23       Impact factor: 3.616

4.  What limits affinity maturation of antibodies in Xenopus--the rate of somatic mutation or the ability to select mutants?

Authors:  M Wilson; E Hsu; A Marcuz; M Courtet; L Du Pasquier; C Steinberg
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.